PE07112009A1 - constant region antibody mutant - Google Patents

constant region antibody mutant

Info

Publication number
PE07112009A1
PE07112009A1 PE2008001679A PE0016792008A PE07112009A1 PE 07112009 A1 PE07112009 A1 PE 07112009A1 PE 2008001679 A PE2008001679 A PE 2008001679A PE 0016792008 A PE0016792008 A PE 0016792008A PE 07112009 A1 PE07112009 A1 PE 07112009A1
Authority
PE
Peru
Prior art keywords
constant region
position
seq id
amino acid
seq
Prior art date
Application number
PE2008001679A
Other languages
Spanish (es)
Inventor
Tomoyuki Igawa
Hirotake Shiraiwa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to JP2007250147 priority Critical
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE07112009A1 publication Critical patent/PE07112009A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40511493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE07112009(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification

Abstract

SE REFIERE A UNA REGION CONSTANTE DE ANTICUERPO HUMANO QUE COMPRENDE SECUENCIAS DE AMINOACIDOS SELECCIONADOS DE SEQ ID N°1, SEQ N°2, SEQ N° 3, SEQ N° 5, SEQ N° 7, ENTRE OTROS, CARACTERIZADO POR: a) UNA REGION CONSTANTE CON SUPRESIONES DE Gly EN POSICION 329 Y Lys EN POSICION 330 EN LA SECUENCIA DE AMINOACIDOS SEQ ID N°1; Refers to a human constant region antibody comprising amino acid sequences SELECTED SEQ ID No. 1, SEQ No. 2, SEQ No. 3, SEQ No. 5, SEQ No. 7, IA, CHARACTERIZED BY: a) CONSTANT rEGION WITH deletions Gly Lys position 329 and position 330 in the amino acid sequence SEQ ID No. 1; b) UNA REGION CONSTANTE CON SUPRESIONES DE Gly EN LA POSICION 325 Y Lys EN LA POSICION 326 EN LA SECUENCIA DE AMINOACIDOS SEQ ID N°2; b) A CONSTANT REGION WITH deletions Gly at position 325 and Lys at position 326 in the amino acid sequence SEQ ID No. 2; c) UNA REGION CONSTANTE CON SUPRESIONES DE Gly EN LA POSICION 326 Y Lys EN LA POSICION 327 EN LA SECUENCIA DE AMINOACIDOS SEQ ID N°3. c) a constant region with deletions Gly at position 326 and Lys at position 327 in the amino acid sequence SEQ ID No. 3. SE REFIERE TAMBIEN REGION CONSTANTE DE IgG2 CARACTERIZADO POR AMINOACIDOS EN POSICIONES 209, 218, 276, 14, 102, ENTRE OTROS, DE SEQ ID N°2 HAN SIDO SUSTITUIDOS POR OTROS AMINOACIDOS. Also relates IgG2 constant region CHARACTERIZED BY AMINO ACID POSITIONS IN 209, 218, 276, 14, 102, among others, SEQ ID No. 2 have been replaced by other amino acids. ASI COMO REGION CONSTANTE DE IgG4 CARACTERIZADO POR AMINOACIDOS EN LAS POSICIONES 14, 16, 20, 21, 97, ENTRE OTROS DE SEQ ID N°3 HAN SIDO SUSTITUIDOS POR OTROS AMINOACIDOS WELL AS IgG4 constant region CHARACTERIZED BY amino acids at positions 14, 16, 20, 21, 97, among others SEQ ID No. 3 have been replaced by other amino acids
PE2008001679A 2007-09-26 2008-09-26 constant region antibody mutant PE07112009A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007250147 2007-09-26

Publications (1)

Publication Number Publication Date
PE07112009A1 true PE07112009A1 (en) 2009-07-15

Family

ID=40511493

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001679A PE07112009A1 (en) 2007-09-26 2008-09-26 constant region antibody mutant

Country Status (23)

Country Link
US (2) US9688762B2 (en)
EP (3) EP3059246B1 (en)
JP (5) JP5484060B2 (en)
KR (3) KR20180126633A (en)
CN (1) CN101874041B (en)
AR (3) AR068563A1 (en)
AU (1) AU2008304748C1 (en)
BR (1) BRPI0817273A2 (en)
CA (2) CA2700394C (en)
DK (2) DK3059246T3 (en)
ES (2) ES2687808T3 (en)
HK (1) HK1146728A1 (en)
IL (1) IL204537D0 (en)
MX (2) MX2010003450A (en)
MY (1) MY163473A (en)
PE (1) PE07112009A1 (en)
PH (1) PH12014502106A1 (en)
PL (1) PL3059246T3 (en)
RU (2) RU2526512C2 (en)
SG (2) SG193868A1 (en)
TW (2) TWI464262B (en)
WO (1) WO2009041613A1 (en)
ZA (1) ZA201002422B (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5620626B2 (en) 2005-03-31 2014-11-05 中外製薬株式会社 Polypeptide production method by association control
CN101330929B (en) * 2005-10-14 2014-03-05 学校法人福冈大学 Inhibitor of transplanted islet dysfunction in islet transplantation
AR058135A1 (en) * 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agents for the treatment of heart diseases
AR057582A1 (en) * 2005-11-15 2007-12-05 Nat Hospital Organization Agents to suppress the induction of cytotoxic T lymphocytes
CN101370521A (en) * 2006-01-27 2009-02-18 学校法人庆应义塾;中外制药株式会社 Remedy for disease associated with choroidal angiogenesis
WO2007114319A1 (en) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
CN105177091A (en) * 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody
CN101495146B (en) 2006-04-07 2012-10-17 国立大学法人大阪大学 Muscle regeneration promoter
PT2047863E (en) 2006-06-08 2013-10-21 Chugai Pharmaceutical Co Ltd Preventive or remedy for inflammatory disease
WO2008090901A1 (en) * 2007-01-23 2008-07-31 Shinshu University Chronic rejection inhibitor
EP3059246B1 (en) 2007-09-26 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
AU2008304778B9 (en) 2007-09-26 2014-05-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
JP5139517B2 (en) * 2008-12-05 2013-02-06 中外製薬株式会社 Anti-NR10 antibody and use thereof
AU2008332276B2 (en) 2007-12-05 2014-02-27 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
BRPI0821110A2 (en) 2007-12-05 2015-07-07 Chugai Pharmaceutical Co Ltd Anti nr-10 antibody and use of it
PL2708559T3 (en) * 2008-04-11 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2310415B8 (en) 2008-04-25 2017-12-13 Dyax Corp. Antibodies against fcrn and use thereof
CA2728243A1 (en) * 2008-06-05 2009-12-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd
JP2010210772A (en) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
TW201900878A (en) * 2009-03-19 2019-01-01 日商中外製藥股份有限公司 Antibody constant region altered body
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI440470B (en) * 2009-03-19 2014-06-11 Chugai Pharmaceutical Co Ltd Pharmaceutical formulation containing improved antibody molecules
WO2010107108A1 (en) * 2009-03-19 2010-09-23 中外製薬株式会社 Rheumatoid arthritis treatment agent
PE05622012A1 (en) 2009-05-15 2012-06-06 Chugai Pharmaceutical Co Ltd Anti-axl
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2497498A4 (en) 2009-11-05 2013-04-17 Univ Osaka Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
TWI505838B (en) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody
JP5104996B2 (en) 2010-01-29 2012-12-19 東レ株式会社 Polylactic acid resin sheet
JP5889181B2 (en) * 2010-03-04 2016-03-22 中外製薬株式会社 Antibody constant region variants
WO2011149051A1 (en) 2010-05-28 2011-12-01 中外製薬株式会社 Antitumor t cell response enhancer
CA2806252C (en) * 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
GB201014033D0 (en) * 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
TR201802772T4 (en) 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Blood coagulation factor VIII having an alternative function, for multi-specific antibody binding molecules in function.
CN103429737A (en) * 2010-11-30 2013-12-04 中外制药株式会社 Cytotoxicity-inducing therapeutic agent
CN103260640B (en) 2010-12-23 2015-12-02 詹森生物科技公司 An active protease-resistant antibody Fc mutants
US9182672B2 (en) 2010-12-23 2015-11-10 Eulitha Ag System and method for production of nanostructures over large areas
US20140050733A1 (en) * 2011-02-07 2014-02-20 Dale B. Schenk Apoe immunotherapy
WO2012115241A1 (en) 2011-02-25 2012-08-30 中外製薬株式会社 Fcγriib-specific fc antibody
TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
WO2012167039A1 (en) 2011-06-02 2012-12-06 Dyax Corp. Fc RECEPTOR BINDING PROTEINS
MX340498B (en) 2011-06-30 2016-07-11 Chugai Pharmaceutical Co Ltd Heterodimerized polypeptide.
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
WO2013022855A1 (en) * 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
JP6310394B2 (en) * 2011-10-10 2018-04-11 ゼンコア インコーポレイテッド Methods for purifying antibodies
CA2859767C (en) * 2011-12-19 2018-09-11 Synimmune Gmbh Bispecific antibody molecule and use thereof for treatment of proliferative disease
TWI593705B (en) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EP2862875A4 (en) 2012-06-14 2016-01-13 Chugai Pharmaceutical Co Ltd ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
JPWO2014030750A1 (en) 2012-08-24 2016-08-08 中外製薬株式会社 Mouse FcγRII specific Fc antibody
WO2014030728A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 Fcγriib-specific fc region variant
EP2940135A4 (en) 2012-12-27 2016-08-03 Chugai Pharmaceutical Co Ltd Heterodimerized polypeptide
CN105073781A (en) 2013-01-11 2015-11-18 加州生物医学研究所 Bovine fusion antibodies
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
TW201835108A (en) 2013-02-01 2018-10-01 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US20160039912A1 (en) 2013-04-02 2016-02-11 Chugai Seiyaku Kabushiki Kaisha Fc REGION VARIANT
US20160159919A1 (en) 2013-06-24 2016-06-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic Agent Comprising Humanized Anti-Epiregulin Antibody as Active Ingredient for Non-Small-Cell Lung Carcinoma Excluding Adenocarcinoma
US20160229915A1 (en) 2013-09-27 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
BR112016010025A2 (en) 2013-11-11 2017-12-05 Chugai Pharmaceutical Co Ltd antigen binding molecule containing modified antibody variable region
WO2015099165A1 (en) 2013-12-27 2015-07-02 中外製薬株式会社 Method for purifying antibody having low isoelectric point
EA201691925A1 (en) 2014-03-28 2017-06-30 Ксенкор, Инк. Bispecific antibodies that bind with cd38 and cd3
WO2015188135A1 (en) * 2014-06-06 2015-12-10 The California Institute For Biomedical Research Constant region antibody fusion proteins and compositions thereof
EA201790674A1 (en) 2014-09-26 2017-08-31 Чугаи Сейяку Кабусики Кайся Cytotoxic inducing therapeutic agent
EP3221363A2 (en) 2014-11-21 2017-09-27 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
US9605080B2 (en) 2014-11-21 2017-03-28 Bristol-Myers Squibb Company Antibodies against CD73
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223845A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
RU2017123731A (en) 2014-12-19 2019-01-09 Чугаи Сеияку Кабусики Кайся Antibodies to myostatin, polyepeptides containing options of fc regions, and ways of their application
EP3233921A4 (en) 2014-12-19 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
EA201791754A1 (en) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся ANTIBODIES CONTAINING ANTIGEN-BINDING DOMAIN DEPENDING ON THE CONCENTRATION OF IONS, Fc-AREA OPTIONS, IL-8-CONNECTING ANTIBODIES AND THEIR APPLICATIONS
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
AU2016304764A1 (en) * 2015-08-07 2018-03-01 Imaginab, Inc. Antigen binding constructs to target molecules
CN108699136A (en) 2015-12-07 2018-10-23 Xencor股份有限公司 Heterodimeric antibodies that bind cd3 and psma
CA3029328A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
WO2019077092A1 (en) 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag Method for generating multispecific antibodies from monospecific antibodies
WO2019086362A1 (en) 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15133A (en) * 1856-06-17 Machine fob paring
US117097A (en) * 1871-07-18 Improvement in brick-machines
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US5126250A (en) * 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
BG60017A3 (en) 1988-09-28 1993-06-15 Lilly Co Eli Method for reducing the heterogeneity of monoclonal antibodies
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3370324B2 (en) 1991-04-25 2003-01-27 中外製薬株式会社 Reshaped human antibody against human interleukin-6 receptor
US5468634A (en) 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
ZA9306260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
BR9204244A (en) 1992-10-26 1994-05-03 Cofap Gray cast iron
JPH08503617A (en) 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Reactivity of humanized antibody to L- selectin
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
ES2156587T3 (en) 1993-08-02 2001-07-01 Merck Patent Gmbh Bispecific molecules that recognize antigen starter lymphocytic CD2 and tumor antigens.
IL107742D0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
DE122009000068I2 (en) 1994-06-03 2011-06-16 Ascenion Gmbh A process for producing heterologous bispecific antibodies
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0783893B1 (en) 1994-10-07 2012-04-04 Chugai Seiyaku Kabushiki Kaisha Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
CN100350973C (en) 1994-10-21 2007-11-28 岸本忠三 Drug composition for curing disease produced from IL-6
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
MX9706538A (en) 1995-02-28 1997-11-29 Procter & Gamble Preparation of noncarbonated beverage products having superior microbial stability.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0811691B1 (en) 1995-09-11 2004-12-01 Kyowa Hakko Kogyo Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
CZ399A3 (en) 1996-07-19 1999-06-16 Amgen Inc. Polypeptide analogs of cation-active polypeptides
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
ES2246069T3 (en) 1997-05-02 2006-02-01 Genentech, Inc. Process for preparing multispecific antibodies and multimeric having common components.
US5980893A (en) 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
IL135221D0 (en) 1997-10-03 2001-05-20 Chugai Pharmaceutical Co Ltd Natural humanized antibody and methods for the preparation thereof
ES2299241T3 (en) 1998-03-17 2008-05-16 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for inflammatory bowel diseases containing antagonist antibodies of IL-6 receptor.
WO1999051743A1 (en) 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (en) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド Generation of modified molecules having increased serum half-life
AU764211C (en) 1998-12-01 2006-03-30 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
DK1188830T3 (en) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd New hæmopoietinreceptorprotein NR10
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SE9903895D0 (en) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
WO2001075454A2 (en) 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
AU2001266272B2 (en) 2000-05-03 2005-09-15 Medigene Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
WO2002036165A1 (en) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
JP4336498B2 (en) 2000-12-12 2009-09-30 ザ ボード オブ レジェンツ−ザ ユニバーシティー オブ テキサス システム Molecules and compositions thereof having an extended half-life and applications
KR20090010127A (en) 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 Expression technology for proteins containing a hybrid isotype antibody moiety
RU2361613C2 (en) 2001-04-02 2009-07-20 Тугаи Сейяку Кабусики Кайся Therapeutic agent for diseases, related to children's chronic arthritic diseases
MY138286A (en) * 2001-04-13 2009-05-29 Biogen Idec Inc Antibodies to vla-1
AT407204T (en) 2001-06-22 2008-09-15 Chugai Pharmaceutical Co Ltd Cell proliferation inhibitors with anti-glypican-3 antibody
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
EP1464702A4 (en) 2001-12-28 2005-09-21 Chugai Pharmaceutical Co Ltd Method of stabilizing protein
EP2840089A1 (en) 2002-01-18 2015-02-25 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
SI2230299T1 (en) 2002-01-18 2012-07-31 Zymogenetics Inc Novel cytokine ZCYTOR17 ligand
US20030224397A1 (en) 2002-02-11 2003-12-04 Genentech, Inc. Antibody variants with faster antigen association rates
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20050130224A1 (en) 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
JP2004086862A (en) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc Apparatus, method and program for processing protein interaction information, and recording medium
WO2003105757A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
TWI322814B (en) 2002-07-22 2010-04-01 Chugai Pharmaceutical Co Ltd
JP2005535341A (en) 2002-08-15 2005-11-24 エピトミスク インコーポレーティッド Humanized rabbit antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0224082D0 (en) 2002-10-16 2002-11-27 Celltech R&D Ltd Biological products
US7223393B2 (en) 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
CA2517926A1 (en) 2003-03-04 2004-10-28 Alexion Pharmaceuticals, Inc. Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
ES2347657T3 (en) 2003-03-24 2010-11-03 Zymogenetics, Inc. Antibodies directed against IL-22RA and binding partners and method of use in inflammation.
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
AU2004256042A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. BlyS antagonists and uses thereof
WO2004113387A2 (en) * 2003-06-24 2004-12-29 Merck Patent Gmbh Tumour necrosis factor receptor molecules with reduced immunogenicity
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005035753A1 (en) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP2311945A1 (en) 2003-10-14 2011-04-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies substituting for functional proteins
JP2008504002A (en) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Neonatal Fc receptor (FcRn) binding polypeptide variants, dimeric Fc binding protein, and methods related thereto
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
DK1711207T3 (en) 2003-12-10 2013-03-11 Medarex Inc Interferon-alpha antibodies and their use
PT1691837E (en) 2003-12-10 2012-08-27 Medarex Inc Ip-10 antibodies and their uses
AR048210A1 (en) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd A preventive agent for vasculitis.
CA2550996A1 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
NL1027975C2 (en) 2004-01-09 2005-12-23 Pfizer Antibodies to MAdCAM.
ES2341461T5 (en) 2004-02-11 2014-10-29 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-IL-6
KR20070035482A (en) 2004-03-24 2007-03-30 각고호우징 게이오기주크 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient
WO2005090405A1 (en) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha Subtype of humanized antibody against interleukin-6 receptor
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
AR048335A1 (en) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd therapeutic agents to inner ear disorders comprising an antagonist of IL-6 as an active ingredient
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp Antibodies against human interleukin-13 and uses thereof
WO2006004663A2 (en) 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
EP1774019B1 (en) 2004-07-06 2011-10-12 Bioren, Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
AU2005272993B2 (en) 2004-07-15 2010-02-11 Xencor, Inc Optimized Fc variants
JP2008511337A (en) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッドGenentech,Inc. Heteromultimeric molecule
WO2006030200A1 (en) 2004-09-14 2006-03-23 National Institute For Biological Standards And Control Vaccine
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US7928205B2 (en) 2004-10-22 2011-04-19 Amgen Inc. Methods for refolding of recombinant antibodies
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
WO2006067847A1 (en) 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha Method of preparing antibody by use of cell having its fucose transporter function inhibited
CA2592015A1 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
KR101564713B1 (en) 2004-12-28 2015-11-06 이나뜨 파르마 2 monoclonal antibodies against nkg2a
AU2006204791A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc Antibodies and Fc fusion proteins with altered immunogenicity
EP1847602B1 (en) 2005-01-12 2014-04-23 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG2 ANTIBODIES
AU2006214404B2 (en) 2005-02-14 2012-03-08 Bristol-Myers Squibb Company Methods of treating skin disorders using an IL-31RA antagonist
JP5620626B2 (en) 2005-03-31 2014-11-05 中外製薬株式会社 Polypeptide production method by association control
WO2006106903A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
JP4917024B2 (en) 2005-04-08 2012-04-18 中外製薬株式会社 Blood coagulation factor VIII functional substitute antibody
JP5222720B2 (en) 2005-04-15 2013-06-26 ジェネンテック, インコーポレイテッド HGF β chain mutant
AU2006239851B2 (en) 2005-04-26 2011-06-16 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PE13242006A1 (en) 2005-04-29 2007-01-15 Centocor Inc anti-IL-6 antibodies, compositions, methods and uses
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Antibodies directed against the beta amyloid peptide and methods using the same.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP2221316A1 (en) 2005-05-05 2010-08-25 Duke University Anti-CD19 antibody therapy for autoimmune disease
EP1908482B1 (en) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US20090028854A1 (en) 2005-06-10 2009-01-29 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
MX2008000030A (en) 2005-07-11 2008-04-02 Macrogenics Inc Methods of treating autoimmune disease using humanized anti-cd16a antibodies.
ES2579602T3 (en) * 2005-08-10 2016-08-12 Macrogenics, Inc. Identification and modification of antibodies with Fc regions variants and methods of use of these
WO2007032634A1 (en) 2005-09-12 2007-03-22 Industry Foundation Of Chonnam National University A method for production of mature natural killer cell
JP2009510102A (en) * 2005-09-29 2009-03-12 ヴァイラル ロジック システムズ テクノロジー コーポレーション Immunomodulatory compositions and the use thereof
CN101330929B (en) 2005-10-14 2014-03-05 学校法人福冈大学 Inhibitor of transplanted islet dysfunction in islet transplantation
AR058135A1 (en) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agents for the treatment of heart diseases
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
WO2007074880A1 (en) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilizing preparation
JP2009528264A (en) 2006-01-10 2009-08-06 ザイモジェネティクス,インコーポレイティド Method of treating pain and inflammation in nerve tissue using il-31 antagonist
KR101459159B1 (en) 2006-01-12 2014-11-12 알렉시온 파마슈티칼스, 인코포레이티드 Antibodies to ox-2/cd200 and uses thereof
TW200808347A (en) 2006-03-23 2008-02-16 Kirin Brewery Agonistic antibody directed against human thrombopoietin receptor
CN101421303B (en) 2006-03-23 2013-06-12 生命北极神经科学公司 Improved protofibril selective antibodies and the use thereof
CN105177091A (en) 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody
WO2007114319A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
CN101495146B (en) 2006-04-07 2012-10-17 国立大学法人大阪大学 Muscle regeneration promoter
TWI422387B (en) 2006-05-25 2014-01-11 Glaxo Group Ltd Immunoglobulins
EP2374818B1 (en) 2006-06-02 2012-12-19 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
PT2047863E (en) 2006-06-08 2013-10-21 Chugai Pharmaceutical Co Ltd Preventive or remedy for inflammatory disease
WO2007147122A2 (en) 2006-06-15 2007-12-21 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
JPWO2008090960A1 (en) 2007-01-24 2010-05-20 協和発酵キリン株式会社 Recombinant antibody composition which specifically binds to ganglioside gm2
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2008100995A1 (en) 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
PL2426144T3 (en) 2007-02-23 2019-05-31 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
JPWO2008114733A1 (en) 2007-03-16 2010-07-01 協和発酵キリン株式会社 Anti-Claudin-4 antibody
ES2593484T3 (en) 2007-03-29 2016-12-09 Genmab A/S Bispecific antibodies and their production methods
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP2155790A1 (en) 2007-05-31 2010-02-24 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
EP2031064A1 (en) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Method for increasing protein titres
US20100226925A1 (en) * 2007-09-14 2010-09-09 Amgen Inc. Homogeneous Antibody Populations
AU2008304778B9 (en) 2007-09-26 2014-05-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
EP3059246B1 (en) 2007-09-26 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
WO2009041734A1 (en) 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. Agonistic antibody against human thrombopoietin receptor
WO2009041621A1 (en) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
AR066172A1 (en) 2007-09-28 2009-07-29 Chugai Pharmaceutical Co Ltd Method for the preparation of an anti-glypican 3 antibody with modulated plasma kinetics by varying the plasma half-life.
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
ES2400107T3 (en) 2007-10-22 2013-04-05 Merck Serono S.A. IFN-beta fused to a single Fc fragment of IgG mutated
US9175091B2 (en) 2007-11-15 2015-11-03 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
KR20160062207A (en) 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 Anti-NR10 antibody and use thereof
BRPI0821110A2 (en) 2007-12-05 2015-07-07 Chugai Pharmaceutical Co Ltd Anti nr-10 antibody and use of it
AU2008332276B2 (en) 2007-12-05 2014-02-27 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
WO2009079649A1 (en) 2007-12-18 2009-06-25 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
SI2235064T1 (en) 2008-01-07 2016-04-29 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN101952454B (en) 2008-02-08 2014-06-04 米迪缪尼有限公司 Anti-IFNAR1 antibodies with reduced Fc ligand affinity
PL2708559T3 (en) 2008-04-11 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
ES2487846T3 (en) 2008-05-01 2014-08-25 Amgen, Inc. anti-hepcindina antibodies and methods of use
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd
AR074438A1 (en) 2008-12-02 2011-01-19 Pf Medicament Process for modulating the antagonistic activity of a monoclonal antibody
WO2010064090A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
JP2010210772A (en) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TW201900878A (en) 2009-03-19 2019-01-01 日商中外製藥股份有限公司 Antibody constant region altered body
PE05622012A1 (en) 2009-05-15 2012-06-06 Chugai Pharmaceutical Co Ltd Anti-axl
CN103833855A (en) 2009-06-26 2014-06-04 瑞泽恩制药公司 Readily isolated bispecific antibodies with native immunoglobulin format
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
RU2606264C2 (en) 2009-12-25 2017-01-10 Чугаи Сеияку Кабушики Каиша Method of modification of polypeptide for purification of polypeptide multimers
EA201492253A1 (en) 2009-12-29 2015-06-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Constructors connecting with ron and methods of their use
US8846397B2 (en) 2010-01-20 2014-09-30 Merck Sharp & Dohme Corp. Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
WO2011091177A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
ES2602971T3 (en) 2010-03-02 2017-02-23 Kyowa Hakko Kirin Co., Ltd. Modified antibody composition
JP5889181B2 (en) 2010-03-04 2016-03-22 中外製薬株式会社 Antibody constant region variants
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
KR20180135993A (en) 2010-04-20 2018-12-21 젠맵 에이/에스 Heterodimeric antibody fc-containing proteins and methods for production thereof
KR20180053775A (en) 2010-04-23 2018-05-23 제넨테크, 인크. Production of heteromultimeric proteins
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
EP2699263A4 (en) 2011-04-20 2014-12-24 Liquidating Trust Methods for reducing an adverse immune response to a foreign antigen in a human subject with anti-cd4 antibodies or cd4-binding fragments thereof or cd4-binding molecules
US10344050B2 (en) 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
JP6326371B2 (en) 2011-11-04 2018-05-16 ザイムワークス,インコーポレイテッド Stable heterodimeric antibody design with mutations in the Fc domain
CA2889951A1 (en) 2012-11-02 2014-05-08 Zymeworks Inc. Crystal structures of heterodimeric fc domains
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
WO2014144960A2 (en) 2013-03-15 2014-09-18 Abbvie Biotherapeutics Inc. Fc variants
US20160229915A1 (en) 2013-09-27 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer

Also Published As

Publication number Publication date
ES2687808T3 (en) 2018-10-29
TW200925273A (en) 2009-06-16
MY163473A (en) 2017-09-15
AR110887A2 (en) 2019-05-15
US9688762B2 (en) 2017-06-27
EP3059246B1 (en) 2018-07-11
SG10201605394SA (en) 2016-08-30
WO2009041613A1 (en) 2009-04-02
TW201429986A (en) 2014-08-01
MX342551B (en) 2016-10-04
ZA201002422B (en) 2014-06-25
IL204537D0 (en) 2010-11-30
EP3415529A1 (en) 2018-12-19
JP2016169220A (en) 2016-09-23
CN101874041A (en) 2010-10-27
EP3059246A1 (en) 2016-08-24
KR20180126633A (en) 2018-11-27
AU2008304748B2 (en) 2014-01-16
KR101680906B1 (en) 2016-11-30
PL3059246T3 (en) 2018-11-30
PH12014502106A1 (en) 2015-12-07
JP2016026215A (en) 2016-02-12
JP5868441B2 (en) 2016-02-24
JP6385386B2 (en) 2018-09-05
BRPI0817273A2 (en) 2015-06-16
US20100298542A1 (en) 2010-11-25
JP2019001794A (en) 2019-01-10
TWI464262B (en) 2014-12-11
CN101874041B (en) 2013-06-19
JP5484060B2 (en) 2014-05-07
US20170342154A1 (en) 2017-11-30
AR068563A1 (en) 2009-11-18
DK3059246T3 (en) 2018-10-01
CA2978687A1 (en) 2009-04-02
DK2194066T3 (en) 2016-05-02
JPWO2009041613A1 (en) 2011-01-27
JP2014144956A (en) 2014-08-14
JP5930503B2 (en) 2016-06-08
AR110822A2 (en) 2019-05-08
EP2194066A4 (en) 2010-12-15
KR20100074221A (en) 2010-07-01
KR20160135850A (en) 2016-11-28
AU2008304748C1 (en) 2014-06-12
HK1146728A1 (en) 2014-03-21
KR101922788B1 (en) 2018-11-27
ES2566957T3 (en) 2016-04-18
MX2010003450A (en) 2010-04-27
CA2700394C (en) 2017-10-24
SG193868A1 (en) 2013-10-30
EP2194066A1 (en) 2010-06-09
RU2526512C2 (en) 2014-08-20
EP2194066B1 (en) 2016-03-09
CA2700394A1 (en) 2009-04-02
AU2008304748A1 (en) 2009-04-02
RU2010116278A (en) 2011-11-10
TWI563002B (en) 2016-12-21
RU2014122609A (en) 2015-12-10

Similar Documents

Publication Publication Date Title
DOP2007000016A (en) Cytotoxic agents comprising new tomaymycin derivatives.
CL2010001146A1 (en) recombinant protein porcine circovirus type 2 (PCV2); use of the recombinant protein to prevent infection by PCV2; a container comprising the immunogenic composition (div exp 3475-2005).
ECSP099514A (en) Activin-actrii antagonists and uses to increase red blood cell levels
TW200815466A (en) Antibodies
MY158438A (en) Antibodies against human angiopoietin 2
HRP20110129T1 (en) Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol
AR079345A1 (en) oxyntomodulin peptide analogue
NZ553239A (en) Process for concentration of antibodies and proteins
MXPA04008822A (en) Monocyclic aroylpyridinones as antiinflammatory agents.
RU2005123979A (en) The surgical tool to be run in multiple launchers pressing action, the mechanism comprising of electroactive polymer against movement in the opposite direction
LTPA2018010I1 (en) Human anti-IL-23 antibodies, compositions, methods, and uses
CR10852A (en) Bicyclic compounds and their use as antidiabetic
GT200600240A (en) anti-TrkB monoclonal antibodies and uses thereof
AT553501T (en) photovoltaic cell
TW200819427A (en) N'-cyano-N-halogenalkylimidamide derivatives
TW200806656A (en) Substituted enaminocarbonyl compounds
UA110599C2 (en) Peptides for immunotherapy of tumors, including neuronal tumors and brain tumors
WO2003096989A3 (en) Anti tubercular drug: compositions and methods
EA200702408A1 (en) Glucagon-like peptide-2 analogues (glp-2)
MY165889A (en) Compositions and methods of using proislet peptides and analogs thereof
CR10192A (en) Amido compounds and their use as pharmaceuticals
MX2009002999A (en) Protease resistant insulin analogues.
GB2438802A (en) Structure of the hepatitis C virus NS5A protein
MXPA06000708A (en) Novel aminobenzophenone compounds.
AR070690A1 (en) Methods and compositions using Klotho fusion polypeptides-fgf (fibroblast growth factor)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed